Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma

Oncology

Volumn 58, Issue 4, 2000, Pages 273-279

  Szelenyi H ^a   Hohenberger, P ^b   Lochs, H ^b   Haboubi, N ^c   Berdel, W E ^d   Thiel, E ^a   Kreuser, E D ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c US Bioscience   (United States)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

5 Fluorouracil; Colorectal carcinoma; First line chemotherapy; Trimetrexate

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; FLUOROURACIL; FOLINIC ACID; LOPERAMIDE; TRIMETREXATE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM ULCER; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTPATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; STATISTICS; VOMITING;

EID: 0342657719     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012112     Document Type: Article

References (30)

1. Cunningham D, Findlay M: The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 1993;29A:2077-2079.
2. Wakefield SE, Wheeler DW, Mortensen NJ, Kettlewell MG: The incidence and Dukes' staging of colorectal cancer over 3 decades. Eur J Surg Oncol 1998;24:525-527.
3. Anonymous: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project [see comments]. J Clin Oncol 1992;10: 896-903.
4. Kemeny N, Golbey R: A chemotherapeutic approach to colorectal carcinoma: in Stearns MW Jr (ed): Neoplasms of the Colon, Rectum and Anus. New York, Wiley, 1980, pp 156-168.
5. Poon MA, O'Connell MJ, Moertel CG, Wicand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie J, Tschetter I.K: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-1418.
6. Anonymous: Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1994;12: 960-969.
7. Lin JT, Bertino JR: Update on trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties. Cancer Invest 1991;9: 159-172.
8. Bertino JR, Sawicki WL, Moroson BA, Cashmore AR, Elslager EF: 2,4-diamino-5-methyl-6 - [(3,4,5 - trimethoxyanilino)methyl]quinazoline (tmq), a potent non-classical folate antagonist inhibitor-1. Effect on dihydrofolate reductase and growth of rodent tumors in vitro and in vivo. Biochem Pharmacol 1979;28: 1983-1987.
9. Kamen BA, Eibl B, Cashmore A, Bertino J: Uptake and efficacy of trimetrexate (TMQ. 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitro. Biochem Pharmacol 1984;33:1697-1699.
10. Rodenhuis S, McGuire JJ, Sawicki WL, Bertino JR: Effects of methotrexate and of the 'non-classical' folate antagonist trimetrexate on human leukemia cells. Leukemia 1987;1:116-120.
11. Leopold WR, Dykes DJ, Griswold DP Jr: Therapeutic synergy of trimetrexate (CI-898) in combination with doxorubicin, vineristine, cytoxan, 6-thioguanine, cisplatin, or 5-fluorouracil against intraperitoneally implanted P388 leukemia. NCI Monogr 1987, pp 99-104.
12. Elliott WL, Howard CT, Dykes DJ, Leopold WR: Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice. Cancer Res 1989; 49:5586-5590.
13. Sobrero A, Romanini A, Russello O, Nicolin A, Rosso R, Bertino JR: Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: Implications for the mechanism of this interaction. Eur J Cancer Clin Oncol 1989;25:977-982.
14. Conti JA, Kemeny N, Seiter K, Goker E, Tong W, Andre M, Ragusa K, Bertino JR: Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. J Clin Oncol 1994;12:695-700.
15. Bleiberg H: Role of chemotherapy for advanced colorectal cancer: New opportunities. Semin Oncol 1996;23:42-50.
16. Polyzos A, Tsavaris N, Giannopoulos A, Bacoyiannis C, Papadimas V, Kalahanis N, Karatzas G, Kosmas C, Sakelaropoulos N, Archimandritis A, Papachristodoulou A, Kosmiois P: Biochemical modulation of fluorouracil: Comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: A randomized trial. Cancer Chemother Pharmacol 1996;38: 292-297.
17. Romanini A, Li WW, Colofiore JR, Bertino JR: Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/ fluorouracil, in CCRF-CEM cells. J Natl Cancer Inst 1992;84:1033-1038.
18. Romanini A, Lin JT, Niedzwiecki D, Bunni M, Priest DG, Bertino JR: Role of folylpolyglutamates in biochemical modulation of fluoropyrimidines by leucovorin. Cancer Res 1991;51: 789-793.
19. Lin JT, Bertino JR: Trimetrexate: A second generation folate antagonist in clinical trial. J Clin Oncol 1987;5:2032-2040.
20. Petrelli N, Douglass HO Jr, Herrera L, Russell D, Stablein DM, Bruckner HW, Mayor RJ, Schinella R, Green MD, Muggia FM: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. Gastrointestinal Tumor Study Group [published erratum appears in J Clin Oncol 1990;8:185]. J Clin Oncol 1989;7:1419-1426.
21. Blanke CD, Kasimis B, Schein P, Capizzi R, Kurman M: Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. J Clin Oncol 1997;15:915-920.
22. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M: Phase II study of irinotecan in the fluorouracil-based chemotherapy. J Clin Oncol 1997;15:251-260.
23. Conti JA, Kemeny N, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C: Irinotecan (CPT 11) is an active agent in previously untreated patients with colorectal carcinoma. J Clin Oncol 1996;14:709-715.
24. Saltz LB, Locker PK, Pirotta N, Elfring GL, Miller L: Weekly irinotecan (Cpt 11), leucovorin (LV), and fluorouracil (FU) is superior to daily X5 LV/FU in patients with previously untreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:989.
25. Zalcberg JR, Cunningham D, Van Cutsem E, Francois E, Schornagel J, Adenis A, Green M, Iveson A, Azab M, Seymour I: ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. J Clin Oncol 1996;14:716-721.
26. Cunningham D, Zalcberg JR, Rath U, Olver I, Van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G: 'Tomudex' (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomadex' Colorectal Cancer Study Group. Eur J Cancer 1995;31A:1945-1954.
27. Becouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF, Nasca S, Nguyen TD, Paillot B, Raoul JL, Duffour J, Fandi A, Dupont-Andre G, Rougier P: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998;16:2739-2744.
28. Levi F, Zidani R, Misset JL: Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil and folinic acid in metastatic colorectal cancer. International Organization of Cancer Chronotherapy. Lancet 1997;350:681-686.
29. Extra JM, Marty M, Brienza S, Misset JL: Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998;25:13-22.
30. Punt CJ, Keizer HJ, Douma J, Schüller J, Skovsgaard T, ten Napel CHH, Lochs H, Muller EW, Habboubi N, Wagener DJT: Multicenter randomized trial of 5-fluorouracil and leucovorin with or without trimetrexate as first line treatment in patients with advanced colorectal carcinoma (abstract). Proc Am Soc Clin Oncol 1999;18:1006.